Inhibition of Mycobacterium tuberculosis InhA (Enoyl-acyl carrier protein reductase) by synthetic Chalcones: a molecular modelling analysis and in-vitro evidence

J Biomol Struct Dyn. 2023 Jul-Aug;41(12):5399-5417. doi: 10.1080/07391102.2022.2086922. Epub 2022 Jun 24.

Abstract

Tuberculosis (TB) is a serious infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). The World Health Organization (WHO) estimates that 1.8 million people die each year from TB, with 10 million new cases being registered each year. In this study, 50 Chalcones were developed, five of which were synthesized, and their inhibitory effects against Mtb were studied. The discovery of new powerful inhibitors with IC50 values in the sub-micro molar range resulted from the development of structure-activity relationships (SAR). The goal of the molecular modelling studies was to uncover the most important structural criteria underpinning the binding affinity and selectivity of this class of inhibitors as possible anti-TB drugs. Because of their great efficacy and selectivity, our developed nitro and benzyloxy substituted Chalcones compounds appear to be promising anti-TB therapies.Communicated by Ramaswamy H. Sarma.

Keywords: Chalcones; InhA; Mycobacterium tuberculosis; molecular modelling; toxicity.

MeSH terms

  • Acyl Carrier Protein / metabolism
  • Acyl Carrier Protein / pharmacology
  • Antitubercular Agents / chemistry
  • Bacterial Proteins / chemistry
  • Chalcones* / pharmacology
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis*
  • Oxidoreductases / metabolism
  • Structure-Activity Relationship
  • Tuberculosis* / drug therapy
  • Tuberculosis* / microbiology

Substances

  • Chalcones
  • Acyl Carrier Protein
  • Antitubercular Agents
  • Oxidoreductases
  • Bacterial Proteins